Uncategorized
Study: Systemic vascular risk higher with intensive treatment with ranibizumab for AMD
An intravitreal dose of ranibizumab for treatment of age-related macular degeneration is small, but it can affect systemic vasculature, according to one study author.“Many ophthalmologists do not realize the possible increase in the systemic vascular risks by injecting ranibizumab for AMD. I assume this is because the frequency of [cerebrovascular accidents] and other systemic vascular adverse events is low — usually up to several percentages of AMD patients per year,” Takashi Ueta, MD, PhD, principal investigator, told Ocular Surgery News. “However, our meta-analysis, by including data for more than 6,500 (Read more...)